Company Overview
Cabaletta Bio is a late-stage clinical biotechnology company focused on developing targeted cell therapies specifically for patients with autoimmune diseases.
Key Financial Figures
Revenue
The company’s statements of operations do not report any top-line revenue.
Earnings Per Share (EPS)
The net loss per share (basic and diluted) was $(0.40) for the fourth quarter of 2025 and $(2.10) for the full year 2025.
Additional Financial Insights
Full-year research and development expenses reached $142.7 million, contributing to a total net loss of $167.8 million for 2025. Cabaletta Bio ended the year with $133.6 million in cash, cash equivalents, and short-term investments. Combined with an additional $30.0 million raised in the first quarter of 2026, the company expects its capital to fund operations into the fourth quarter of 2026.
The post Cabaletta Bio Q4 and FY 2025 Financial Review first appeared on Alphastreet.
